We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Our new plant for CHO based mAb or Recombinant Protein manufacturing is ready for the qualification phase.

Lugano / Barbengo, February 14 2013

Our new plant for CHO based mAb or Recombinant Protein manufacturing is ready for the qualification phase.
Cerbios-Pharma SA (from now on “Cerbios”) is proud to announce that the construction phase for our new Biotechnology plant is almost concluded.

The “state-of-the-art” biologics plant is dedicated to the production of monoclonal antibodies or therapeutic recombinant proteins based on a CHO platform under cGMP and authorization by Swissmedic for the production of
clinical and commercial batches is planned during Q3 / 2013.

This facility will allow Cerbios to strengthen its position as a contract manufacturer for the production of New Biological Entities (NBE) for clinical studies, while until now Cerbios was only supplying material for toxicological studies.
There was a certain delay in the detailed design phase due to comments and observations received from Swissmedic and from our FDA consultant (former FDA inspector for Biotechnology plants audits) during their preliminary reviews.
“I am not frustrated by this delay” confirms Gabriel Haering, Cerbios’ CEO. “

This delay will be compensated by the fact that Cerbios will now be able to serve its partners for global projects (EU, USA, JPN) like for all our other production units.”
In addition, Cerbios has special partnerships in place that will help improve the productivity of the cell lines (at least 3-4 g/liter) received from Start-ups or Universities, including (1) gene synthesis, (2) cloning in an expression vector, and (3) transfection.

For partners already having a cell line with good productivity, the service provided by Cerbios R&D could include (1) cell line optimization, (2) process industrialization, and (3) GMP cell bank manufacturing prior to a move to GMP production for clinical trials

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
[[ getItemTitle(currentIndex) ]]